|
[1]T. Inoue, J. Widder, L. V. van Dijk, et al., "Limited impact of setup and range uncertainties, breathing motion, and interplay effects in robustly optimized intensity modulated proton therapy for stage III non-small cell lung cancer," International Journal of Radiation Oncology* Biology* Physics, vol. 96, pp. 661-669, 2016. [2]R. Malyapa, M. Lowe, A. Bolsi, et al., "Evaluation of robustness to setup and range uncertainties for head and neck patients treated with pencil beam scanning proton therapy," International Journal of Radiation Oncology* Biology* Physics, vol. 95, pp. 154-162, 2016. [3]M. Moteabbed, A. Trofimov, G. Sharp, et al., "Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations," Physics in Medicine & Biology, vol. 62, p. 1644, 2017. [4]T. Netherton, Y. Li, P. Nitsch, et al., "Interplay effect on a 6‐MV flattening‐filter‐free linear accelerator with high dose rate and fast multi‐leaf collimator motion treating breast and lung phantoms," Medical physics, vol. 45, pp. 2369-2376, 2018. [5]P. C. Park, X. R. Zhu, A. K. Lee, et al., "A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties," International Journal of Radiation Oncology* Biology* Physics, vol. 82, pp. e329-e336, 2012. [6]M.-C. Biston, S. Chiavassa, V. Grégoire, et al., "Time of PTV is ending, robust optimization comes next," Cancer/Radiothérapie, 2020. [7]R. Ricotti, D. Ciardo, G. Fattori, et al., "Intra-fraction respiratory motion and baseline drift during breast Helical Tomotherapy," Radiotherapy and Oncology, vol. 122, pp. 79-86, 2017. [8]M. Lizondo, A. Latorre-Musoll, M. Ribas, et al., "Pseudo skin flash on VMAT in breast radiotherapy: Optimization of virtual bolus thickness and HU values," Physica Medica, vol. 63, pp. 56-62, 2019. [9]A. Dunlop, R. Colgan, A. Kirby, et al., "Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy," Clinical and translational radiation oncology, vol. 16, pp. 60-66, 2019. [10]Y. Gao, X. Wu, Y. Li, et al., "The Predictive Value of MLR for Radiation Pneumonia During Radiotherapy of Thoracic Tumor Patients," Cancer Management and Research, vol. 12, p. 8695, 2020. [11]P.-J. Chao, H.-F. Lee, J.-H. Lan, et al., "Propensity-score-matched evaluation of the incidence of radiation pneumonitis and secondary cancer risk for breast cancer patients treated with IMRT/VMAT," Scientific reports, vol. 7, pp. 1-9, 2017. [12]丁慧敏, 郭仕賢, 藍仁鴻, et al., "乳癌患者接受放射治療後發生放射性肺炎之萊曼正常組織併發症機率模型參數分析," 放射治療與腫瘤學, vol. 24, pp. 25-34, 2017. [13]J. Ödén, I. Toma-Dasu, K. Eriksson, et al., "The influence of breathing motion and a variable relative biological effectiveness in proton therapy of left-sided breast cancer," Acta Oncologica, vol. 56, pp. 1428-1436, 2017. [14]L. Z. Braunstein and O. Cahlon, "Potential morbidity reduction with proton radiation therapy for breast cancer," in Seminars in radiation oncology, 2018, pp. 138-149. [15]A. J. Lomax, L. Cella, D. Weber, et al., "Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes," International Journal of Radiation Oncology* Biology* Physics, vol. 55, pp. 785-792, 2003. [16]O. Jäkel and P. Reiss, "The influence of metal artefacts on the range of ion beams," Physics in Medicine & Biology, vol. 52, p. 635, 2007. [17]S. Van Der Voort, S. Van De Water, Z. Perkó, et al., "Robustness recipes for minimax robust optimization in intensity modulated proton therapy for oropharyngeal cancer patients," International Journal of Radiation Oncology* Biology* Physics, vol. 95, pp. 163-170, 2016. [18]M. Cubillos-Mesías, E. G. Troost, F. Lohaus, et al., "Including anatomical variations in robust optimization for head and neck proton therapy can reduce the need of adaptation," Radiotherapy and Oncology, vol. 131, pp. 127-134, 2019. [19]S. S. Korreman, "Motion in radiotherapy: photon therapy," Physics in Medicine & Biology, vol. 57, p. R161, 2012. [20]E. L. Lorenzen, C. Brink, C. W. Taylor, et al., "Uncertainties in estimating heart doses from 2D-tangential breast cancer radiotherapy," Radiotherapy and Oncology, vol. 119, pp. 71-76, 2016. [21]Y.-F. Li, L. Chang, W.-H. Li, et al., "Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: A meta-analysis," The Breast, vol. 27, pp. 93-98, 2016. [22]F. Tommasino, M. Durante, V. D'Avino, et al., "Model-based approach for quantitative estimates of skin, heart, and lung toxicity risk for left-side photon and proton irradiation after breast-conserving surgery," Acta Oncologica, vol. 56, pp. 730-736, 2017. [23]H. S. Gabryś, F. Buettner, F. Sterzing, et al., "Design and selection of machine learning methods using radiomics and dosiomics for normal tissue complication probability modeling of xerostomia," Frontiers in oncology, vol. 8, p. 35, 2018. [24]A. Ankolekar, A. Dekker, R. Fijten, et al., "The benefits and challenges of using patient decision aids to support shared decision making in health care," JCO clinical cancer informatics, vol. 2, pp. 1-10, 2018. [25]D. Jette and W. Chen, "Creating a spread-out Bragg peak in proton beams," Physics in Medicine & Biology, vol. 56, p. N131, 2011. [26]H. Paganetti, "Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer," Physics in Medicine & Biology, vol. 59, p. R419, 2014. [27]M. Soukup, M. Fippel, and M. Alber, "A pencil beam algorithm for intensity modulated proton therapy derived from Monte Carlo simulations," Physics in Medicine & Biology, vol. 50, p. 5089, 2005. [28]H. S. W. C. Tseung, J. Ma, C. R. Kreofsky, et al., "Clinically applicable Monte Carlo–based biological dose optimization for the treatment of head and neck cancers with spot-scanning proton therapy," International Journal of Radiation Oncology* Biology* Physics, vol. 95, pp. 1535-1543, 2016. [29]M. Stuschke, A. Kaiser, J. A. Jawad, et al., "Multi-scenario based robust intensity-modulated proton therapy (IMPT) plans can account for set-up errors more effectively in terms of normal tissue sparing than planning target volume (PTV) based intensity-modulated photon plans in the head and neck region," Radiation Oncology, vol. 8, pp. 1-5, 2013. [30]H. Miura, S. Ozawa, and Y. Nagata, "Efficacy of robust optimization plan with partial‐arc VMAT for photon volumetric‐modulated arc therapy: A phantom study," Journal of applied clinical medical physics, vol. 18, pp. 97-103, 2017. [31]T.-F. Lee, F.-M. Fang, P.-J. Chao, et al., "Dosimetric comparisons of helical tomotherapy and step-and-shoot intensity-modulated radiotherapy in nasopharyngeal carcinoma," Radiotherapy and Oncology, vol. 89, pp. 89-96, 2008. [32]B. Emami, J. Lyman, A. Brown, et al., "Tolerance of normal tissue to therapeutic irradiation," International Journal of Radiation Oncology* Biology* Physics, vol. 21, pp. 109-122, 1991. [33]L. H. T. Leung, M. W. K. Kan, A. C. K. Cheng, et al., "A new dose–volume-based Plan Quality Index for IMRT plan comparison," Radiotherapy and Oncology, vol. 85, pp. 407-417, 2007. [34]T. Schultheiss, L. Kun, K. Ang, et al., "Radiation response of the central nervous system," International Journal of Radiation Oncology* Biology* Physics, vol. 31, pp. 1093-1112, 1995. [35]H. A. Gay, J.-Y. Jin, A. J. Chang, et al., "Utility of normal tissue-to-tumor α/β ratio when evaluating isodoses of isoeffective radiation therapy treatment plans," International Journal of Radiation Oncology* Biology* Physics, vol. 85, pp. e81-e87, 2013. [36]J. Kang, R. Schwartz, J. Flickinger, et al., "Machine learning approaches for predicting radiation therapy outcomes: a clinician's perspective," International Journal of Radiation Oncology* Biology* Physics, vol. 93, pp. 1127-1135, 2015. [37]許正憲, "應用最小絕對壓縮挑選運算子與馬氏田口系統特徵選取提升乳癌放射治療併發症之預測能力," 國立高雄科技大學 電子工程系 研究所學位論文, 2017. [38]V. Barnett and T. Lewis, "Outliers in statistical data," Wiley Series in Probability and Mathematical Statistics. Applied Probability and Statistics, 1984. [39]L. Prokhorenkova, G. Gusev, A. Vorobev, et al., "CatBoost: unbiased boosting with categorical features," arXiv preprint arXiv:1706.09516, 2017. [40]A. V. Dorogush, V. Ershov, and A. Gulin, "CatBoost: gradient boosting with categorical features support," arXiv preprint arXiv:1810.11363, 2018. [41]V. Charles, "E-model for transportation problem of linear stochastic fractional programming," Optimization online. http://www. optimizationonline. org, 1997. [42]D. Stacey, F. Légaré, K. Lewis, et al., "Decision aids for people facing health treatment or screening decisions," Cochrane database of systematic reviews, 2017. [43]D. J. DeFalco and J. A. DeFalco, "–FIRST MEASURE EVERYTHING: ENGINEERING TRENDS IN DATA VISUALIZATION," Design Recommendations for Intelligent Tutoring Systems, p. 47. [44]X. Wan, W. Wang, J. Liu, et al., "Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range," BMC medical research methodology, vol. 14, pp. 1-13, 2014. [45]E. W. Korevaar, S. J. Habraken, D. Scandurra, et al., "Practical robustness evaluation in radiotherapy–A photon and proton-proof alternative to PTV-based plan evaluation," Radiotherapy and Oncology, vol. 141, pp. 267-274, 2019. [46]A. T. Berman, B.-K. K. Teo, D. Dolney, et al., "An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer," Radiation oncology, vol. 8, pp. 1-11, 2013. [47]L. Cella, V. D’Avino, G. Palma, et al., "Modeling the risk of radiation-induced lung fibrosis: Irradiated heart tissue is as important as irradiated lung," Radiotherapy and Oncology, vol. 117, pp. 36-43, 2015. [48]V. Moiseenko, W. Y. Song, L. K. Mell, et al., "A comparison of dose-response characteristics of four NTCP models using outcomes of radiation-induced optic neuropathy and retinopathy," Radiation Oncology, vol. 6, pp. 1-10, 2011. [49]Y. Seppenwoolde, J. V. Lebesque, K. De Jaeger, et al., "Comparing different NTCP models that predict the incidence of radiation pneumonitis," International Journal of Radiation Oncology* Biology* Physics, vol. 55, pp. 724-735, 2003. [50]P. Svolos, I. Tsougos, G. Kyrgias, et al., "On the use of published radiobiological parameters and the evaluation of NTCP models regarding lung pneumonitis in clinical breast radiotherapy," Australasian physical & engineering sciences in medicine, vol. 34, pp. 69-81, 2011. [51]N. Kavousi, H. A. Nedaie, S. Gholami, et al., "Ipsilateral lung normal tissue complication probability parameters for different dose calculation algorithms in radiotherapy of breast cancer," Journal of Cancer Research and Therapeutics, vol. 16, p. 1323, 2020. [52]T.-F. Lee, P.-J. Chao, L. Chang, et al., "Developing multivariable normal tissue complication probability model to predict the incidence of symptomatic radiation pneumonitis among breast cancer patients," PloS one, vol. 10, p. e0131736, 2015. [53]P. A. Lind, B. Wennberg, G. Gagliardi, et al., "ROC curves and evaluation of radiation-induced pulmonary toxicity in breast cancer," International Journal of Radiation Oncology* Biology* Physics, vol. 64, pp. 765-770, 2006. [54]Z. Kahán, M. Csenki, Z. Varga, et al., "The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients," International Journal of Radiation Oncology* Biology* Physics, vol. 68, pp. 673-681, 2007. [55]E. M. Werner, M. C. Eggert, S. Bohnet, et al., "Prevalence and characteristics of pneumonitis following irradiation of breast cancer," Anticancer research, vol. 39, pp. 6355-6358, 2019. [56]M. V. Graham, J. A. Purdy, B. Emami, et al., "Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)," International Journal of Radiation Oncology* Biology* Physics, vol. 45, pp. 323-329, 1999. [57]T. Marinko, "Pericardial disease after breast cancer radiotherapy," Radiology and oncology, vol. 53, pp. 1-5, 2018. [58]C. A. Jensen, A. M. A. Roa, M. Johansen, et al., "Robustness of VMAT and 3DCRT plans toward setup errors in radiation therapy of locally advanced left-sided breast cancer with DIBH," Physica Medica, vol. 45, pp. 12-18, 2018. [59]D. Wiant, S. Wentworth, H. Liu, et al., "How important is a reproducible breath hold for deep inspiration breath hold breast radiation therapy?," International Journal of Radiation Oncology* Biology* Physics, vol. 93, pp. 901-907, 2015. [60]W. W. Lam, M. Kwok, M. Chan, et al., "Does the use of shared decision-making consultation behaviors increase treatment decision-making satisfaction among Chinese women facing decision for breast cancer surgery?," Patient education and counseling, vol. 94, pp. 243-249, 2014. [61]J. M. Hasak, T. M. Myckatyn, V. F. Grabinski, et al., "Stakeholders’ perspectives on postmastectomy breast reconstruction: recognizing ways to improve shared decision making," Plastic and reconstructive surgery Global open, vol. 5, 2017.
|